Table 1

Baseline characteristics of patients with rheumatoid arthritis ever receiving only oral DMARDs, adalimumab (ADA), etanercept (ETN) or infliximab (INF)

Age (years)61.2±13.156.14±13.155.6±13.360.4±13.5
Women (%)72.879.579.973.7
Disease duration (years)9.8±9.811.3±9.612.0±9.911.3±9.3
Private insurance (%)71.871.480.777.3
Medicare (%)44.230.635.442.4
College education (%)44.953.956.250.6
Smoker (%)14.518.214.915.2
History alcohol abuse (%)302616
History of liver disorder (%)
Body mass index29.1±7.329.2±7.229.2±7.629.4±7.2
Visits per year3.
RF+ (%)72.274.575.873.2
Blood draws for AST/ALT/year4.0±2.63.2±2.43.6±2.52.7±2.5
Folate use (%)45.954.636.046.3
Tender joint count3.25±5.14.77±6.23.81±5.33.63±5.3
Swollen joint count4.25±5.45.67±6.54.02±4.95.02±6.3
  • Data are presented as proportions or mean±SD.

  • * Columns are not mutually exclusive as patients may have contributed exposure time to more than one of these categories; total N=6861.

  • Variables found significant in univariate analysis and used in multivariate models.

  • Some subjects have private insurance and Medicare.

  • Additional variables evaluated and not found significant in univariate analysis: history of cardiovascular disease (myocardial infarction, coronary artery disease, congestive heart failure), history of diabetes, history of hypertension, physician-assessed disease activity, patient visual analogue score for general health, patient visual analogue score for pain, use of non-steroidal anti-inflammatory drugs.

  • ALT, alanine aminotransferase; AST, aspartate aminotransferase; CDAI, Clinical Disease Activity Index; DAS28, disease activity score 28; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; RF, rheumatoid factor.